Freenome, an early cancer detection company developing blood-based tests to identify cancer at its most treatable stage, ...

As more home-based care providers rely on AI tools for both clinical advancements and operational streamlining, the ...

On track to submit GraftAssureDx™ for FDA review by year-endOn track for commitment to have 20 transplant centers globally ...

Arima Genomics, Inc., a company leveraging whole-genome sequence and structure information to provide comprehensive cancer therapy selection insights, today announced that the Aventa(TM) Lymphoma test ...

In this GEN webinar, experts from Sampled and Rady Children’s Hospital will discuss the validation and clinical integration ...

Q3 U.S. Galleri Revenue Grew 28% Year-Over-Year to $32.6 Million Q3 Galleri Tests Sold Grew 39% Year-Over-Year to More Than 45,000 Galleri PMA Submission ...

The answer, of course, is two. But how about three? The developer of a blood-based breast cancer assay, BCAL Diagnostics (ASX:BDX) has scored the trifecta by acquiring the local rights for ovarian and ...

SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for oncology, and inflammatory and infectious diseases, today announced it has been ...

Natera, Inc. , a global leader in cell-free DNA and precision medicine, today announced another successful readout for its ECD program, which is evaluating a blood-based screening test for the ...

Revvity, Inc. (NYSE: RVTY) today announced a program for expansion of its type 1 diabetes (T1D) offering to include a population-scale assay for early detection with support from Sanofi (EURONEXT: SAN ...

Ensuring quality and compliance is at the core of every successful clinical laboratory. This webinar brings together CAP ...

This achievement marks the company's second CLIA certification in 2025, following its San Diego facility earlier this year, underscoring Crown Bioscience's continued commitment to expanding its global ...